Cobio Diagnostics, founded in 2016 and based in Golden, Colorado, is a biotechnology company dedicated to developing advanced diagnostics for bacterial identification and phenotypic antibiotic resistance testing. The company's core mission is to combat the growing threat of antibiotic resistance, which poses significant risks to global health, food security, and development. Cobio Diagnostics offers innovative diagnostic solutions aimed at accurately identifying bacterial infections and determining their resistance profiles, thereby enabling more effective treatment strategies.

Notable figures affiliated with Cobio Diagnostics include experts in biotechnology and healthcare, although specific names are not provided. The company has attracted attention from investors interested in addressing critical public health challenges. Key achievements include the development of cutting-edge diagnostic tools that have the potential to significantly reduce the incidence of antibiotic-resistant infections. Cobio Diagnostics' impact lies in its contribution to improving patient outcomes and supporting global efforts to manage antibiotic resistance.